GlassScriptPhysician profile
Sara L Farmer
NPI 1538597992
$2,227.99
in general payments reported to CMS, 2019-2025
26 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $567 · 2023: $784 · 2024: $577 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $279.80 | 2022-2024 | Arikayce |
| Abbvie INC. | $227.76 | 2022-2024 | |
| Melinta Therapeutics, LLC | $175.49 | 2022-2024 | Kimyrsa, Vabomere, Rezzayo |
| Glaxosmithkline, LLC. | $155.28 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $142.86 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Grifols USA, LLC | $123.65 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Shionogi INC | $120.94 | 2022-2024 | Fetroja |
| Gilead Sciences, INC. | $99.55 | 2022-2024 | Veklury |
| Ferring Pharmaceuticals INC. | $97.02 | 2022-2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $81.08 | 2022-2024 | Evusheld, Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $78.62 | 2024-2025 | |
| Dexcom, INC. | $77.16 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Novo Nordisk INC | $65.10 | 2025 | Rybelsus, Ozempic |
| Csl Behring | $62.68 | 2022-2023 | Hizentra |
| Astellas Pharma US INC | $59.06 | 2023 | Cresemba |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.43 | 2023-2024 | Cuvitru, Hyqvia |
| Lilly USA, LLC | $57.78 | 2024-2025 | Mounjaro |
| Amgen INC. | $46.46 | 2024-2025 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $45.13 | 2022 | |
| Hospira, INC. | $35.90 | 2024 | |
| Medtronic, INC. | $32.98 | 2025 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $29.29 | 2024 | Nuzyra |
| Exact Sciences Corporation | $27.62 | 2024-2025 | Cologuard Collection Kit |
| Pharming Healthcare, INC. | $16.72 | 2022 | |
| Convatec INC. | $15.87 | 2023 | |
| Abiomed | $15.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.